Thompson Davis & Co’s GSK GSK Stock Holding History

Thompson Davis & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$40K	Buy	800 +300	+60%	+$15.2K	0.09%	238
2018 Q2	$25K	Sell	500 -200	-29%	-$10.1K	0.06%	280
2018 Q1	$34K	Buy	700 +100	+17%	+$4.66K	0.09%	227
2017 Q4	$27K	Sell	600 -584	-49%	-$27K	0.06%	274
2017 Q3	$60K	Sell	1,184 -32	-3%	-$1.62K	0.11%	199
2017 Q2	$66K	Hold	1,216	–	–	0.11%	180
2017 Q1	$64K	Hold	1,216	–	–	0.09%	202
2016 Q4	$59K	Buy	1,216 +228	+23%	+$11.3K	0.1%	211
2016 Q3	$53K	Sell	988 -200	-17%	-$11K	0.09%	222
2016 Q2	$64K	Buy	1,188 +68	+6%	+$3.58K	0.1%	199
2016 Q1	$57K	Buy	1,120 +200	+22%	+$9.96K	0.08%	218
2015 Q4	$46K	Hold	920	–	–	0.06%	272
2015 Q3	$44K	Buy	920 +216	+31%	+$11.2K	0.06%	285
2015 Q2	$37K	Buy	704 +24	+4%	+$1.35K	0.04%	372
2015 Q1	$39K	Sell	680 -52	-7%	-$2.98K	0.05%	346
2014 Q4	$39K	Buy	732 +320	+78%	+$17.9K	0.05%	332
2014 Q3	$24K	Buy	+412	New	+$25.3K	0.03%	422
2014 Q2	–	Sell	-200	Closed	-$13K	–	791
2014 Q1	$13K	Buy	+200	New	+$13.5K	0.02%	447

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Thompson Davis & Co's GSK Position: Q3 2018 in Review

Thompson Davis & Co increased its GSK (GSK) stake by 60% in Q3 2018, buying an estimated $15.2K and bringing the position to 800 shares worth $40K. The position accounts for 0.09% of the portfolio, ranked #238.

Thompson Davis & Co first reported a position in GSK in Q1 2014 and has held it in 18 quarters since. The position peaked at $66K in Q2 2017. 787 funds tracked by Wall St. Rank hold GSK as of Q3 2018.

Thompson Davis & Co held 800 shares of GSK worth $40K as of Q3 2018.
Thompson Davis & Co bought 300 GSK shares in Q3 2018, an estimated $15.2K.
GSK made up 0.09% of Thompson Davis & Co's portfolio in Q3 2018, its #238 holding.
Thompson Davis & Co first reported a position in GSK in Q1 2014 and has held it in 18 quarters since.
Thompson Davis & Co's GSK position peaked at $66K in Q2 2017.
787 funds tracked by Wall St. Rank held GSK as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.